Zelira TherapeuticsASX:ZLD FCF Yield % is -82.48 as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, Zelira Therapeutics ranks worse than 88.5% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Zelira Therapeutics FCF Yield % Related Terms
Zelira Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Zelira Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ZLD vs ENSC, PPCB, ACUT: FCF Yield % Comparison
For the Biotechnology subindustry, Zelira Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics (ASX:ZLD) has a FCF Yield % of -82.48 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #1255 out of 1418 companies in the Biotechnology industry, placing it in the top 88.5%.
Is Zelira Therapeutics' FCF Yield % too high?
Zelira Therapeutics' current FCF Yield % is -82.48. Based on the distribution chart, Zelira Therapeutics ranks #1255 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Zelira Therapeutics' FCF Yield % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #1255 out of 1418 companies for FCF Yield %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current FCF Yield % is -82.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current FCF Yield % of -82.48. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current FCF Yield % is -82.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current FCF Yield % is -82.48 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ZLD has been successfully added to your 